Advancing the Frontiers of Myelodysplastic Syndromes

Andrew Brunner, MD, of Massachusetts General Hospital and Harvard Medical School discusses the latest advancements in the understanding and management of myelodysplastic syndromes (MDS). He discusses the integration of molecular profiling into diagnostic and risk stratification processes, highlighting tools like the IPSS-M calculator that combine genomic data with clinical parameters to personalize patient care. Dr. Brunner also explores promising clinical trials, such as the SELECT-MDS1 and VERONA studies, which are investigating novel therapeutic combinations for patients with high-risk MDS.

Furthermore, Dr. Brunner addresses current gaps in MDS research and clinical practice, emphasizing the need for more inclusive studies and improved access to cutting-edge treatments across diverse patient populations.